Pieris Pharmaceuticals Announces Dosing of First Patient in Phase I Combination Trial for PRS-343 Plus Anti-PD-L1 Immunotherapy
pharmaceutical investing Pieris Pharmaceuticals Appoints Ingmar Bruns, M.D., Ph.D., as Vice President of Clinical Development
Homerun Resources Inc. Announces Positive Bankable Feasibility Study on Solar Glass Manufacturing Plant in Brazil, Confirming Strong Economics and Strategic First-Mover Position in the Americas
Prismo Metals Reports Positive Results from Reconnaissance Mapping and Sampling at Silver King Project, Arizona
